• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.基于初始纤维蛋白原与白蛋白比值和血小板计数分析预测 COVID-19 重症。
Platelets. 2020 Jul 3;31(5):674-679. doi: 10.1080/09537104.2020.1760230. Epub 2020 May 5.
2
The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study.血细胞计数作为预测 COVID-19 疾病进展的潜在生物标志物:一项回顾性研究。
Clin Chem Lab Med. 2020 Jun 25;58(7):1106-1115. doi: 10.1515/cclm-2020-0377.
3
Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19.新冠肺炎患者 D-二聚体和中性粒细胞-淋巴细胞比值的动态变化作为预后生物标志物。
Respir Res. 2020 Jul 3;21(1):169. doi: 10.1186/s12931-020-01428-7.
4
Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score.COVID-19 肺炎患者进展风险预测:CALL 评分。
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399. doi: 10.1093/cid/ciaa414.
5
A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study.用于预测 COVID-19 合并实体瘤患者死亡率的列线图:一项多中心回顾性队列研究。
J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-001314.
6
[Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019].2019冠状病毒病患者D-二聚体浓度与炎症因子或器官功能的关系
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 May;32(5):559-563. doi: 10.3760/cma.j.cn121430-20200414-00518.
7
The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China.新冠肺炎患者中性粒细胞与淋巴细胞比值和 D-二聚体的临床意义:中国苏州的一项回顾性研究。
Thromb Res. 2020 Aug;192:3-8. doi: 10.1016/j.thromres.2020.05.006. Epub 2020 May 6.
8
Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.新型冠状病毒肺炎重型患者静脉血栓栓塞症发病情况。
J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6.
9
Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China.中国武汉严重肺炎患者的临床特征。
Respiration. 2020;99(8):649-657. doi: 10.1159/000507940. Epub 2020 Aug 25.
10
Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.SARS-CoV-2 感染患者凝血功能的显著变化。
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. doi: 10.1515/cclm-2020-0188.

引用本文的文献

1
Investigation of prolonged PCR positivity in COVID-19 patients.新冠病毒感染患者PCR检测持续呈阳性的调查。
Medicine (Baltimore). 2025 Jul 25;104(30):e43581. doi: 10.1097/MD.0000000000043581.
2
Clinical Characteristics and Prognostic Factors of Severe COVID-19.重症新型冠状病毒肺炎的临床特征及预后因素
Infect Drug Resist. 2025 Jun 25;18:3117-3125. doi: 10.2147/IDR.S525970. eCollection 2025.
3
Clinical characteristics of adult asthma patients hospitalized by COVID-19 in Mexico City: a real-world study.墨西哥城因 COVID-19 住院的成年哮喘患者的临床特征:一项真实世界研究。
Ann Med. 2024 Dec;56(1):2424448. doi: 10.1080/07853890.2024.2424448. Epub 2024 Dec 2.
4
The Value of Common Laboratory Markers in Predicting the Severity of COVID-19 Patients.常见实验室指标在预测新型冠状病毒肺炎患者病情严重程度中的价值
Infect Drug Resist. 2024 Nov 13;17:5037-5047. doi: 10.2147/IDR.S478798. eCollection 2024.
5
The association of fibrinogen-albumin ratio and neutrophil-lymphocyte ratio with the severity of respiratory syncytial virus infection in children.纤维蛋白原-白蛋白比值和中性粒细胞-淋巴细胞比值与儿童呼吸道合胞病毒感染严重程度的相关性
Rev Inst Med Trop Sao Paulo. 2024 Apr 19;66:e26. doi: 10.1590/S1678-9946202466026. eCollection 2024.
6
Amino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19.用于预测 COVID-19 患者肺炎早期预后的氨基酸代谢物标志物。
Nat Commun. 2023 Dec 20;14(1):8469. doi: 10.1038/s41467-023-44266-z.
7
Diagnostic Values of Laboratory Biomarkers in Predicting a Severe Course of COVID-19 on Hospital Admission.入院时实验室生物标志物对预测 COVID-19 严重病程的诊断价值。
Biomed Res Int. 2022 Nov 7;2022:5644956. doi: 10.1155/2022/5644956. eCollection 2022.
8
HATCH Score for Predicting Mortality in COVID-19 Patients.预测COVID-19患者死亡率的HATCH评分
Iran J Public Health. 2022 Dec;51(12):2717-2723. doi: 10.18502/ijph.v51i12.11462.
9
Investigation of differences in coagulation characteristics between hospitalized patients with SARS-CoV-2 Alpha, Delta, and Omicron variant infection using rotational thromboelastometry (ROTEM): A single-center, retrospective, observational study.利用旋转血栓弹性描记术(ROTEM)研究住院的 SARS-CoV-2 Alpha、Delta 和奥密克戎变异株感染患者凝血特征的差异:一项单中心、回顾性、观察性研究。
J Clin Lab Anal. 2022 Dec;36(12):e24796. doi: 10.1002/jcla.24796. Epub 2022 Nov 28.
10
Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges.用于COVID-19诊断、预后和严重程度预测的血液生物标志物:机遇与挑战。
J Family Med Prim Care. 2022 Aug;11(8):4330-4341. doi: 10.4103/jfmpc.jfmpc_2283_21. Epub 2022 Aug 30.

本文引用的文献

1
Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.血小板减少症与严重的 2019 年冠状病毒病(COVID-19)感染相关:一项荟萃分析。
Clin Chim Acta. 2020 Jul;506:145-148. doi: 10.1016/j.cca.2020.03.022. Epub 2020 Mar 13.
2
Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression.COVID-19 患者可能受益于持续的洛匹那韦联合治疗方案,而嗜酸性粒细胞的增加可能预测 COVID-19 进展的结果。
Int J Infect Dis. 2020 Jun;95:183-191. doi: 10.1016/j.ijid.2020.03.013. Epub 2020 Mar 12.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
5
Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.一组在中国武汉以外地区感染 2019 年新型冠状病毒(SARS-CoV-2)的患者的临床特征:回顾性病例系列。
BMJ. 2020 Feb 19;368:m606. doi: 10.1136/bmj.m606.
6
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
7
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
8
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学:对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
9
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征:描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
10
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.

基于初始纤维蛋白原与白蛋白比值和血小板计数分析预测 COVID-19 重症。

Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.

机构信息

Taizhou Hospital, Wenzhou Medical University , Linhai, China.

出版信息

Platelets. 2020 Jul 3;31(5):674-679. doi: 10.1080/09537104.2020.1760230. Epub 2020 May 5.

DOI:10.1080/09537104.2020.1760230
PMID:32367765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7212543/
Abstract

Concomitant coagulation disorder can occur in severe patients withCOVID-19, but in-depth studies are limited. This study aimed to describe the parameters of coagulation function of patients with COVID-19 and reveal the risk factors of developing severe disease. This study retrospectively analyzed 113patients with SARS-CoV-2 infection in Taizhou Public Health Center. Clinical characteristics and indexes of coagulation function were collected. A multivariate Cox analysis was performed to identify potential biomarkers for predicting disease progression. Based on the results of multivariate Cox analysis, a Nomogram was built and the predictive accuracy was evaluated through the calibration curve, decision curve, clinical impact curve, and Kaplan-Meier analysis. Sensitivity, specificity, predictive values were calculated to assess the clinical value. The data showed that Fibrinogen, FAR, and D-dimer were higher in the severe patients, while PLTcount, Alb were much lower. Multivariate Cox analysis revealed that FAR and PLT count were independent risk factors for disease progression. The optimal cutoff values for FAR and PLT count were 0.0883 and 13510/L, respectively. The C-index [0.712 (95% CI = 0.610-0.814)], decision curve, clinical impact curve showed that Nomogram could be used to predict the disease progression. In addition, the Kaplan-Meier analysis revealed that potential risk decreased in patients with FAR<0.0883 and PLT count>13510/L.The model showed a good negative predictive value [(0.9474 (95%CI = 0.845-0.986)].This study revealed that FAR and PLT count were independent risk factors for severe illness and the severity of COVID-19 might be excluded when FAR<0.0883 and PLT count>135*10/L.

摘要

伴有凝血功能障碍的重症 COVID-19 患者,但其深入研究有限。本研究旨在描述 COVID-19 患者凝血功能参数,揭示发生重症的危险因素。本研究回顾性分析了泰州市公共卫生中心 113 例 SARS-CoV-2 感染患者的临床特征和凝血功能指标。采用多因素 Cox 分析识别潜在的疾病进展预测标志物。基于多因素 Cox 分析结果,构建 Nomogram 并通过校准曲线、决策曲线、临床影响曲线和 Kaplan-Meier 分析评估预测准确性。计算灵敏度、特异度、预测值以评估临床价值。数据显示,重症患者纤维蛋白原、FAR 和 D-二聚体较高,PLT 计数、Alb 较低。多因素 Cox 分析显示 FAR 和 PLT 计数是疾病进展的独立危险因素。FAR 和 PLT 计数的最佳截断值分别为 0.0883 和 13510/L。C 指数[0.712(95%CI=0.610-0.814)]、决策曲线、临床影响曲线显示 Nomogram 可用于预测疾病进展。此外,Kaplan-Meier 分析显示 FAR<0.0883 和 PLT 计数>13510/L 的患者潜在风险降低。模型显示出良好的阴性预测值[0.9474(95%CI=0.845-0.986)]。本研究表明 FAR 和 PLT 计数是重症的独立危险因素,当 FAR<0.0883 和 PLT 计数>135*10/L 时,COVID-19 的严重程度可能被排除。